WallStSmart

Adlai Nortye Ltd. American Depositary Shares (ANL)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 31159% more annual revenue ($606.42M vs $1.94M). ANL leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

ANL

Avoid

25

out of 100

Grade: F

Growth: 6.3Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: -10.10

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ANL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
118.0%10/10

Revenue surging 118.0% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

ANL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$434.68M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ANL

The strongest argument for ANL centers on Revenue Growth. Revenue growth of 118.0% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : ANL

The primary concerns for ANL are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 5.63 is elevated, increasing financial risk.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

ANL profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

ANL is growing revenue faster at 118.0% — sustainability is the question.

ANL generates stronger free cash flow (-52M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adlai Nortye Ltd. American Depositary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?